Company Overview and News
Shares of Progenics Pharmaceuticals, Inc. (PGNX - Free Report) have declined 12.1% since the close of trading on Sep 12, following the announcement of unsatisfactory data from a phase III study evaluating its imaging agent, 1404, for detecting prostate cancer. The candidate is a prostate specific membrane antigen ("PSMA")-targeted small molecule SPECT/CT imaging agent.
LGNZZ LGND LGNYZ LGNXZ LGNDZ PGNX BHS
Chicago, IL – September 20, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include American Woodmark Corp. (AMWD - Free Report) , Guess', Inc. (GES - Free Report) , Rocky Brands, Inc. (RCKY - Free Report) , W.W.
HLX CATR CAT GES AMD SIVB LB FWRD LGNDZ RCKY HPE GWW LGNZZ LGNYZ LGND HEAR LGNXZ AMWD
2018-09-19 zacks - 1
Chicago, IL – September 19, 2018 - Stocks in this week’s article include: Attunity Ltd. (ATTU - Free Report) , Helix Energy Solutions Group, Inc. (HLX - Free Report) , Ligand Pharmaceuticals (LGND - Free Report) , Turtle Beach Corporation (HEAR - Free Report) and SVB Financial Group (SIVB - Free Report) .
HLX RYAM ATTU ESE SIVB ON CVTI LGNDZ UNFI GTS LGNZZ LGND LGNYZ HEAR LGNXZ INT TSC
A profitable company can not only meet all its business-related costs and expenses, but also provide healthy returns to its investors. The profitability position of a company is measured with the help of a financial ratio. Here, ratio analysis is used to distinguish a profitable company from a loss-making one.
HLX ATTU LGNZZ MDPEB LGND LGNYZ HEAR LGNXZ SIVB MDP LGNDZ
Cytori Therapeutics (CYTX - Free Report) announced that the FDA has granted Orphan Drug designation to its chemotherapy candidate, ATI-1123, for the treatment of small cell lung cancer (“SCLC”).
CYTXW CYTX LGNZZ MDPEB LGND LGNYZ CTYX LGNXZ MDP ILMN LGNDZ
2018-09-15 seekingalpha - 2
Discussion: FibroGen's anti-CTGF antibody pamrevlumab indicated in idiopathic pulmonary fibrosis (IPF) is now under Fast Track review of the FDA. The new status allows a rolling review of the marketing application of the drug. Idiopathic pulmonary fibrosis is a chronic lung disease in which the lung functions progressively decline. The disease is the most common type of interstitial lung disease (ILD) in which interstitium (i.
REDIF RDHL AZN VRCA LGNDZ SHPG VERU FGEN JNJ MRK LGNZZ LGND AVDL LGNYZ LGNXZ PFE
Gilead Sciences, Inc. (GILD - Free Report) announced that it has entered into a strategic collaboration with privately held Precision BioSciences to develop therapies aimed at eliminating hepatitis B virus (HBV) using the latter’s gene editing platform ARCUS.
GILD LGNZZ LGND LGNYZ GLPG LGNXZ ENPH OXY LGNDZ
Endocyte, Inc. (ECYT - Free Report) recently announced that the FDA has accepted radiographic progression free survival (rPFS) as an alternative primary endpoint for the ongoing phase III trial, VISION. The development should support the submission of a New Drug Application (NDA) for full FDA approval of 177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
ECYT CELGZ GILD LGNZZ CELG LGND LGNYZ LGNXZ CG LGNDZ
Alkermes plc (ALKS - Free Report) announced that it has expanded an ongoing phase I study evaluating its immuno-oncology candidate, ALKS 4230. The company a study arm to evaluate ALKS 4230 in combination with FDA-approved PD-1 inhibitor, Merck’s (MRK - Free Report) Keytruda (pembrolizumab) in patients with advanced solid tumors. The study arm will evaluate the safety and anti-tumor activity of ALKS 4230 when administered in combination with Keytruda.
ALKS BIIB LGNZZ LGND LGNYZ LGNXZ LGNDZ
Perrigo Company plc (PRGO - Free Report) announced that the FDA has approved store brand over-the-counter (“OTC”) equivalent of Johnson & Johnson (JNJ - Free Report) owned Imodium Multi-Symptom Relief tablet. The drug is indicated for treating symptoms of diarrhea plus bloating, pressure and cramps.
JNJ LGNZZ LGND PRGO LGNYZ LGNXZ LGNDZ
Strong economic fundamentals and the tax reform have given the small-cap space an edge over the large caps (see all Small Cap ETFs here). Revenues from domestic exposure account for 79.4% for the small-cap stocks on the Russell 2000, marking a substantial difference from the S&P’s 69.7%. As most of the revenues for the small-cap segment come from domestic operations, their business is protected from the global trade crisis.
IWO IJR LGNZZ LGND LGNYZ LGNXZ IJR IWN IJT IWM LGNDZ
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET